Champlain Investment Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $82.8M | Sell |
1,033,497
-700,715
| -40% | -$57.8M | 1.05% | 39 |
|
|
2025
Q4 | $148M | Sell |
1,734,212
-380,325
| -18% | -$31.2M | 1.5% | 10 |
|
|
2025
Q3 | $164M | Sell |
2,114,537
-109,167
| -5% | -$8.53M | 1.24% | 21 |
|
|
2025
Q2 | $174M | Sell |
2,223,704
-388,085
| -15% | -$28.9M | 1.21% | 19 |
|
|
2025
Q1 | $189M | Sell |
2,611,789
-209,924
| -7% | -$15M | 1.37% | 14 |
|
|
2024
Q4 | $209M | Sell |
2,821,713
-258,990
| -8% | -$18.1M | 1.32% | 21 |
|
|
2024
Q3 | $203M | Buy |
3,080,703
+132,515
| +4% | +$9.63M | 1.23% | 29 |
|
|
2024
Q2 | $272M | Sell |
2,948,188
-15,980
| -0.5% | -$1.42M | 1.67% | 10 |
|
|
2024
Q1 | $283M | Buy |
2,964,168
+88,205
| +3% | +$7.41M | 1.62% | 9 |
|
|
2023
Q4 | $219M | Buy |
2,875,963
+108,640
| +4% | +$7.56M | 1.3% | 21 |
|
|
2023
Q3 | $192M | Sell |
2,767,323
-3,170
| -0.1% | -$255K | 1.24% | 20 |
|
|
2023
Q2 | $261M | Buy |
2,770,493
+6,840
| +0.2% | +$595K | 1.61% | 10 |
|
|
2023
Q1 | $229M | Sell |
2,763,653
-189,150
| -6% | -$14.9M | 1.44% | 13 |
|
|
2022
Q4 | $220M | Sell |
2,952,803
-32,213
| -1% | -$2.48M | 1.41% | 13 |
|
|
2022
Q3 | $247M | Sell |
2,985,016
-63,930
| -2% | -$6.15M | 1.68% | 8 |
|
|
2022
Q2 | $290M | Sell |
3,048,946
-36,111
| -1% | -$3.74M | 1.87% | 8 |
|
|
2022
Q1 | $363M | Buy |
3,085,057
+31,560
| +1% | +$3.54M | 1.88% | 4 |
|
|
2021
Q4 | $396M | Sell |
3,053,497
-16,775
| -0.5% | -$1.96M | 1.79% | 4 |
|
|
2021
Q3 | $348M | Sell |
3,070,272
-108,855
| -3% | -$12.4M | 1.66% | 8 |
|
|
2021
Q2 | $329M | Sell |
3,179,127
-16,080
| -0.5% | -$1.52M | 1.57% | 10 |
|
|
2021
Q1 | $267M | Buy |
3,195,207
+371,210
| +13% | +$31.4M | 1.39% | 16 |
|
|
2020
Q4 | $258M | Sell |
2,823,997
-52,145
| -2% | -$4.33M | 1.48% | 14 |
|
|
2020
Q3 | $230M | Buy |
2,876,142
+25,860
| +0.9% | +$2.02M | 1.56% | 17 |
|
|
2020
Q2 | $197M | Buy |
2,850,282
+40,620
| +1% | +$2.89M | 1.41% | 23 |
|
|
2020
Q1 | $177M | Buy |
2,809,662
+85,962
| +3% | +$6.2M | 1.59% | 17 |
|
|
2019
Q4 | $212M | Buy |
2,723,700
+11,490
| +0.4% | +$897K | 1.55% | 11 |
|
|
2019
Q3 | $199M | Buy |
2,712,210
+242,505
| +10% | +$17M | 1.64% | 10 |
|
|
2019
Q2 | $152M | Buy |
2,469,705
+286,005
| +13% | +$17.3M | 1.28% | 28 |
|
|
2019
Q1 | $139M | Buy |
2,183,700
+172,170
| +9% | +$9.83M | 1.21% | 30 |
|
|
2018
Q4 | $103M | Buy |
2,011,530
+34,635
| +2% | +$1.75M | 1.04% | 38 |
|
|
2018
Q3 | $115M | Buy |
1,976,895
+65,925
| +3% | +$3.22M | 1.02% | 40 |
|
|
2018
Q2 | $92.7M | Buy |
1,910,970
+218,895
| +13% | +$10.2M | 0.9% | 46 |
|
|
2018
Q1 | $78.7M | Buy |
1,692,075
+191,055
| +13% | +$8.3M | 0.85% | 53 |
|
|
2017
Q4 | $56.4M | Buy |
+1,501,020
| New | +$55.1M | 0.64% | 72 |
|
|
2016
Q3 | – | Sell |
-478,170
| Closed | -$15.9M | – | 145 |
|
|
2016
Q2 | $15.9M | Sell |
478,170
-682,515
| -59% | -$23.4M | 0.27% | 113 |
|
|
2016
Q1 | $34.1M | Sell |
1,160,685
-88,725
| -7% | -$2.45M | 0.62% | 72 |
|
|
2015
Q4 | $32.9M | Sell |
1,249,410
-296,490
| -19% | -$7.7M | 0.56% | 81 |
|
|
2015
Q3 | $36.6M | Buy |
1,545,900
+19,830
| +1% | +$479K | 0.64% | 67 |
|
|
2015
Q2 | $36.2M | Buy |
1,526,070
+179,940
| +13% | +$4.06M | 0.57% | 82 |
|
|
2015
Q1 | $32M | Sell |
1,346,130
-455,730
| -25% | -$10.2M | 0.55% | 82 |
|
|
2014
Q4 | $38.3M | Sell |
1,801,860
-596,040
| -25% | -$12M | 0.61% | 76 |
|
|
2014
Q3 | $40.8M | Sell |
2,397,900
-413,580
| -15% | -$6.53M | 0.71% | 64 |
|
|
2014
Q2 | $40.2M | Sell |
2,811,480
-606,270
| -18% | -$8.22M | 0.66% | 73 |
|
|
2014
Q1 | $42.2M | Buy |
3,417,750
+622,260
| +22% | +$7.18M | 0.73% | 61 |
|
|
2013
Q4 | $30.6M | Buy |
2,795,490
+906,150
| +48% | +$10.2M | 0.54% | 88 |
|
|
2013
Q3 | $21.9M | Buy |
1,889,340
+231,510
| +14% | +$2.71M | 0.42% | 96 |
|
|
2013
Q2 | $18.6M | Buy |
+1,657,830
| New | +$19.6M | 0.38% | 105 |
|
Other funds holding EW
VCM
VPM
Champlain Investment Partners's EW Position: Q1 2026 in Review
Champlain Investment Partners reduced its Edwards Lifesciences (EW) stake by 40% in Q1 2026, selling an estimated $57.8M and leaving 1,033,497 shares worth $82.8M. The position accounts for 1.05% of the portfolio, ranked #39.
Champlain Investment Partners first reported a position in EW in Q2 2013 and has held it in 47 quarters since. The position peaked at $396M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Champlain Investment Partners held 1,033,497 shares of Edwards Lifesciences worth $82.8M as of Q1 2026.
- Champlain Investment Partners sold 700,715 Edwards Lifesciences shares in Q1 2026, an estimated $57.8M.
- Edwards Lifesciences made up 1.05% of Champlain Investment Partners's portfolio in Q1 2026, its #39 holding.
- Champlain Investment Partners first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 47 quarters since.
- Champlain Investment Partners's Edwards Lifesciences position peaked at $396M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Champlain Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.